Over the past decade Roche and Novartis consistently spent more on R&D than other big pharma groups, while Abbvie and Astrazeneca have added to their budgets.
Alnylam appears to have turned its Onpattro launch around, but is adamant that investors should have been more patient all along.
The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.
If big biotech cannot deliver innovation investors might start demanding shareholder payout plans that look more like big pharma's.
Disappointing second-quarter sales of Novo Nordisk's GLP-1 agonists, Victoza and its successor Ozempic, raise questions.
Two oncology specialists, Epizyme and Clovis, have been punished for ongoing problems.
Glaxosmithkline is trying to reinvent itself as an oncology company – but it will need to make bolder deals if it wants to succeed.